Marco Bisoffi - Publications

Affiliations: 
Biomedical Sciences University of New Mexico, Albuquerque, NM, United States 
Area:
Toxicology, Biochemistry

44 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Amirrad F, Pytak PA, Sadeghiani-Pelar N, Nguyen JPT, Cauble EL, Jones AC, Bisoffi M. Prostate field cancerization and exosomes: Association between CD9, early growth response 1 and fatty acid synthase. International Journal of Oncology. PMID 32319557 DOI: 10.3892/Ijo.2020.4980  0.535
2019 Park SE, Shamloo K, Kristedja TA, Darwish S, Bisoffi M, Parang K, Tiwari RK. EDB-FN Targeted Peptide-Drug Conjugates for Use against Prostate Cancer. International Journal of Molecular Sciences. 20. PMID 31277465 DOI: 10.3390/Ijms20133291  0.456
2017 Leyba K, Swaminathan R, Jones A, Russell J, Joste N, Bisoffi M, Trujillo K. Combining the sick lobe theory with markers of field cancerization for refinement of a personalized surgical margin. Journal of Surgical Oncology. PMID 28695575 DOI: 10.1002/Jso.24724  0.325
2017 Lebya K, Garcia-Smith R, Swaminathan R, Jones A, Russell J, Joste N, Bisoffi M, Trujillo K. Towards a personalized surgical margin for breast conserving surgery-Implications of field cancerization in local recurrence. Journal of Surgical Oncology. PMID 28054359 DOI: 10.1002/Jso.24469  0.315
2016 Aliabadi HM, Mahdipoor P, Bisoffi M, Hugh JC, Uludag H. Single and Combinational siRNA Therapy of Cancer Cells: Probing Changes in Targeted and non-Targeted Mediators after siRNA Treatment. Molecular Pharmaceutics. PMID 27802596 DOI: 10.1021/Acs.Molpharmaceut.6B00711  0.361
2016 Gabriel KN, Jones AC, Nguyen JP, Antillon KS, Janos SN, Overton HN, Jenkins SM, Frisch EH, Trujillo KA, Bisoffi M. Association and regulation of protein factors of field effect in prostate tissues. International Journal of Oncology. PMID 27634112 DOI: 10.3892/Ijo.2016.3666  0.522
2015 Jones AC, Antillon KS, Jenkins SM, Janos SN, Overton HN, Shoshan DS, Fischer EG, Trujillo KA, Bisoffi M. Prostate field cancerization: deregulated expression of macrophage inhibitory cytokine 1 (MIC-1) and platelet derived growth factor A (PDGF-A) in tumor adjacent tissue. Plos One. 10: e0119314. PMID 25767870 DOI: 10.1371/Journal.Pone.0119314  0.435
2015 Gannon NP, Vaughan RA, Garcia-Smith R, Bisoffi M, Trujillo KA. Effects of the exercise-inducible myokine irisin on malignant and non-malignant breast epithelial cell behavior in vitro International Journal of Cancer. 136: E197-E202. PMID 25124080 DOI: 10.1002/Ijc.29142  0.381
2014 Vaughan RA, Gannon NP, Garcia-Smith R, Licon-Munoz Y, Barberena MA, Bisoffi M, Trujillo KA. β-alanine suppresses malignant breast epithelial cell aggressiveness through alterations in metabolism and cellular acidity in vitro Molecular Cancer. 13. PMID 24460609 DOI: 10.1186/1476-4598-13-14  0.349
2014 Fajardo AM, Bisoffi M. Curcumin Analogs, Oxidative Stress, and Prostate Cancer Cancer: Oxidative Stress and Dietary Antioxidants. 191-202. DOI: 10.1016/B978-0-12-405205-5.00018-0  0.691
2013 Vaughan RA, Garcia-Smith R, Trujillo KA, Bisoffi M. Tumor necrosis factor alpha increases aerobic glycolysis and reduces oxidative metabolism in prostate epithelial cells Prostate. 73: 1538-1546. PMID 23818177 DOI: 10.1002/Pros.22703  0.491
2013 Vaughan RA, Garcia-Smith R, Gannon NP, Bisoffi M, Trujillo KA, Conn CA. Leucine treatment enhances oxidative capacity through complete carbohydrate oxidation and increased mitochondrial density in skeletal muscle cells Amino Acids. 45: 901-911. PMID 23812674 DOI: 10.1007/S00726-013-1538-5  0.314
2013 Vaughan RA, Garcia-Smith R, Dorsey J, Griffith JK, Bisoffi M, Trujillo KA. Tumor necrosis factor alpha induces Warburg-like metabolism and is reversed by anti-inflammatory curcumin in breast epithelial cells International Journal of Cancer. 133: 2504-2510. PMID 23661584 DOI: 10.1002/Ijc.28264  0.394
2013 Michel V, Licon-Munoz Y, Trujillo K, Bisoffi M, Parra KJ. Inhibitors of vacuolar ATPase proton pumps inhibit human prostate cancer cell invasion and prostate-specific antigen expression and secretion International Journal of Cancer. 132: E1-E10. PMID 22945374 DOI: 10.1002/Ijc.27811  0.462
2012 Trujillo KA, Jones AC, Griffith JK, Bisoffi M. Markers of field cancerization: proposed clinical applications in prostate biopsies. Prostate Cancer. 2012: 302894. PMID 22666601 DOI: 10.1155/2012/302894  0.509
2012 Jones AC, Trujillo KA, Phillips GK, Fleet TM, Murton JK, Severns V, Shah SK, Davis MS, Smith AY, Griffith JK, Fischer EG, Bisoffi M. Early growth response 1 and fatty acid synthase expression is altered in tumor adjacent prostate tissue and indicates field cancerization. The Prostate. 72: 1159-70. PMID 22127986 DOI: 10.1002/Pros.22465  0.526
2012 Fajardo AM, MacKenzie DA, Ji M, Deck LM, Vander Jagt DL, Thompson TA, Bisoffi M. The curcumin analog ca27 down-regulates androgen receptor through an oxidative stress mediated mechanism in human prostate cancer cells. The Prostate. 72: 612-25. PMID 21796654 DOI: 10.1002/Pros.21464  0.736
2012 Taylor RM, Severns V, Brown DC, Bisoffi M, Sillerud LO. Prostate cancer targeting motifs: expression of αν β3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts. The Prostate. 72: 523-32. PMID 21748756 DOI: 10.1002/Pros.21454  0.528
2011 Taylor RM, Huber DL, Monson TC, Ali AM, Bisoffi M, Sillerud LO. Multifunctional iron platinum stealth immunomicelles: targeted detection of human prostate cancer cells using both fluorescence and magnetic resonance imaging. Journal of Nanoparticle Research : An Interdisciplinary Forum For Nanoscale Science and Technology. 13: 4717-4729. PMID 22121333 DOI: 10.1007/S11051-011-0439-3  0.434
2011 Trujillo KA, Hines WC, Vargas KM, Jones AC, Joste NE, Bisoffi M, Griffith JK. Breast field cancerization: isolation and comparison of telomerase-expressing cells in tumor and tumor adjacent, histologically normal breast tissue. Molecular Cancer Research : McR. 9: 1209-21. PMID 21775421 DOI: 10.1158/1541-7786.Mcr-10-0424  0.369
2011 Trujillo KA, Heaphy CM, Mai M, Vargas KM, Jones AC, Vo P, Butler KS, Joste NE, Bisoffi M, Griffith JK. Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. International Journal of Cancer. Journal International Du Cancer. 129: 1310-21. PMID 21105047 DOI: 10.1002/Ijc.25788  0.377
2011 Fajardo AM, MacKenzie DA, Deck LM, Jagt DLV, Thompson TA, Bisoffi M. Abstract 2073: Curcumin analog 27 induced reactive oxygen species mediate loss of androgen receptor protein expression in human prostate cancer cells Cancer Research. 71: 2073-2073. DOI: 10.1158/1538-7445.Am2011-2073  0.714
2010 Heaphy CM, Fleet TM, Treat EG, Lee SJ, Smith AY, Davis MS, Griffith JK, Fischer EG, Bisoffi M. Organ-wide telomeric status in diseased and disease-free prostatic tissues. The Prostate. 70: 1471-9. PMID 20687220 DOI: 10.1002/Pros.21182  0.468
2010 Treat EG, Heaphy CM, Massie LW, Bisoffi M, Smith AY, Davis MS, Griffith JK. Telomere DNA content in prostate biopsies predicts early rise in prostate-specific antigen after radical prostatectomy for prostate cancer. Urology. 75: 724-9. PMID 19615720 DOI: 10.1016/J.Urology.2009.04.032  0.469
2010 Fajardo AM, Bowles HJ, MacKenzie DA, Jagt DLV, Bisoffi M, Thompson TA. Abstract 1713: Activation of the aryl hydrocarbon receptor and down-regulation of the androgen receptor in prostate cancer cells by the curcumin analog C48 Cancer Research. 70: 1713-1713. DOI: 10.1158/1538-7445.Am10-1713  0.724
2009 Van Slambrouck S, Hilkens J, Bisoffi M, Steelant WF. AsialoGM1 and integrin alpha2beta1 mediate prostate cancer progression. International Journal of Oncology. 35: 693-9. PMID 19724904 DOI: 10.3892/Ijo_00000381  0.507
2009 Heaphy CM, Griffith JK, Bisoffi M. Mammary field cancerization: molecular evidence and clinical importance. Breast Cancer Research and Treatment. 118: 229-39. PMID 19685287 DOI: 10.1007/S10549-009-0504-0  0.427
2009 Haaland CM, Heaphy CM, Butler KS, Fischer EG, Griffith JK, Bisoffi M. Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization. International Journal of Oncology. 35: 537-46. PMID 19639174 DOI: 10.3892/Ijo_00000365  0.522
2009 Heaphy CM, Bisoffi M, Joste NE, Baumgartner KB, Baumgartner RN, Griffith JK. Genomic instability demonstrates similarity between DCIS and invasive carcinomas. Breast Cancer Research and Treatment. 117: 17-24. PMID 18785004 DOI: 10.1007/S10549-008-0165-4  0.337
2008 Serda RE, Bisoffi M, Thompson TA, Ji M, Omdahl JL, Sillerud LO. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells. The Prostate. 68: 773-83. PMID 18247401 DOI: 10.1002/Pros.20739  0.512
2008 Heaphy CM, Treat EG, Fleet TM, Bisoffi M, Smith AY, Davis MS, Fischer EG, Griffith JK. FIELD EFFECT REVEALED BY 3D-MAPPING OF TELOMERE DNA CONTENT AND ALLELIC IMBALANCE IN WHOLE MOUNT PROSTATES Journal of Urology. 179: 725-725. DOI: 10.1016/S0022-5347(08)62114-X  0.363
2007 Heaphy CM, Bisoffi M, Griffith JK. Diagnostic significance of allelic imbalance in cancer. Expert Opinion On Medical Diagnostics. 1: 159-68. PMID 23489303 DOI: 10.1517/17530059.1.2.159  0.401
2007 Heaphy CM, Baumgartner KB, Bisoffi M, Baumgartner RN, Griffith JK. Telomere DNA content predicts breast cancer-free survival interval. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 7037-43. PMID 18056180 DOI: 10.1158/1078-0432.Ccr-07-0432  0.334
2007 Serda RE, Adolphi NL, Bisoffi M, Sillerud LO. Targeting and cellular trafficking of magnetic nanoparticles for prostate cancer imaging. Molecular Imaging. 6: 277-88. PMID 17711783 DOI: 10.2310/7290.2007.00025  0.411
2007 Heaphy CM, Hines WC, Butler KS, Haaland CM, Heywood G, Fischer EG, Bisoffi M, Griffith JK. Assessment of the frequency of allelic imbalance in human tissue using a multiplex polymerase chain reaction system. The Journal of Molecular Diagnostics : Jmd. 9: 266-71. PMID 17384220 DOI: 10.2353/Jmoldx.2007.060115  0.318
2007 Liu Z, Wan G, Heaphy C, Bisoffi M, Griffith JK, Hu CA. A novel loss-of-function mutation in TP53 in an endometrial cancer cell line and uterine papillary serous carcinoma model. Molecular and Cellular Biochemistry. 297: 179-87. PMID 17119852 DOI: 10.1007/S11010-006-9345-X  0.328
2007 Treat EG, Heaphy CM, Bisoffi M, Griffith JK, Smith AY, Davis MS. 1432: Telomere DNA Content Predicts Biochemical Recurrence in a Retrospective Analysis of Prostate Cancer Biopsies Journal of Urology. 177: 472-473. DOI: 10.1016/S0022-5347(18)31633-1  0.458
2006 Bisoffi M, Heaphy CM, Griffith JK. Telomeres: prognostic markers for solid tumors. International Journal of Cancer. 119: 2255-60. PMID 16858685 DOI: 10.1002/Ijc.22120  0.351
2006 Fordyce CA, Heaphy CM, Bisoffi M, Wyaco JL, Joste NE, Mangalik A, Baumgartner KB, Baumgartner RN, Hunt WC, Griffith JK. Telomere content correlates with stage and prognosis in breast cancer. Breast Cancer Research and Treatment. 99: 193-202. PMID 16752076 DOI: 10.1007/S10549-006-9204-1  0.324
2006 Heaphy CM, Bisoffi M, Fordyce CA, Haaland CM, Hines WC, Joste NE, Griffith JK. Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. International Journal of Cancer. 119: 108-16. PMID 16450377 DOI: 10.1002/Ijc.21815  0.4
2005 Hines WC, Fajardo AM, Joste NE, Bisoffi M, Griffith JK. Quantitative and spatial measurements of telomerase reverse transcriptase expression within normal and malignant human breast tissues. Molecular Cancer Research : McR. 3: 503-9. PMID 16179497 DOI: 10.1158/1541-7786.Mcr-05-0031  0.674
2004 Bisoffi M, Klima I, Gresko E, Durfee PN, Hines WC, Griffith JK, Studer UE, Thalmann GN. Expression profiles of androgen independent bone metastatic prostate cancer cells indicate up-regulation of the putative serine-threonine kinase GS3955. The Journal of Urology. 172: 1145-50. PMID 15311059 DOI: 10.1097/01.Ju.0000135117.40086.Fa  0.477
2003 Bisoffi M, Wetterwald A, Peternae D, Studer U, Cocchini M, Thalmann G. Identification by gene array and regulation of GS3955 putative serine/threonine kinase in the LNCAP model of human prostate cancer progression European Urology Supplements. 2: 59. DOI: 10.1016/S1569-9056(03)80232-4  0.352
2003 Thalmann G, Sikes R, Bisoffi M, Nelson P, Wetterwald A, Studer U, Cecchini M. Gene expression profiles in the LNCAP model of human prostate cancer progression: Upregulation of osteomimetic peptides European Urology Supplements. 2: 58. DOI: 10.1016/S1569-9056(03)80230-0  0.371
Show low-probability matches.